"As a result, GSK now expects to increase its annual
production capacity of Relenza to 190 million treatment courses
by the end of 2009. This represents a threefold increase to
GSK's previous maximum capacity of 60 million treatment
courses," the company said in a statement.
The production will be 190 million by the end of 2009, so why does the idiot say Biota will no recieve money until 2010.
The forward sales of 190m to governments are spoken for and surely progressive payments will follow the Relenza deliveries throughout 2009 and early 2010.
What a wanker.
- Forums
- ASX - By Stock
- BTA
- washington
washington, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)